Product Name: SgK269 (632-638) pY635
Product Number: PE-04AHC99
Size: | 200 µg | | Price: | 47.00 |
| 1 mg | | $US | 94.00 |
Peptide Name: SgK269 (632-638) pY635
Product Use: Services as a blocking peptide for use with the SgK269-pY635 rabbit polyclonal antibody (Cat. No.: AB-PK811) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the N-terminal half of the protein. This is the major in vivo phosphorylation site in SgK269. Phosphorylation induces interaction with Grb2 and stimulates cells growth and motility.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: PNA-pY-DNL
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 1060.01 Da
Peptide Purity Percent after Synthesis and Purification: >95
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: SgK269 - pY635 phosphosite-specific antibody (Cat. No.: AB-PK811) Scientific Background: SgK269 (PEAK1, pseudopodium-enriched atypical kinase 1) is a protein-serine/threonine kinase of the Other group and NKF3 family. It appears to function in the regulation of cell spreading and migration on fibronectin substrates. In addition, SgK269 is predicted to either directly or indirectly affect the phosphorylation of cytoskeleton-associated proteins, such as MAPK1/ERK and PXN. SgK269 has been demonstrated to function downstream of eIF5A1 and eIF5A2, translation initiation factors that have been implicated in several forms of human cancer. For example, the expression of these factors is required for the growth of pancreatic ductal adenocarcinoma (PDAC) cells in vivo and their overexpression in mice models leads to enhanced PDAC cell growth and tumour formation. Downstream activity of PEAK1 is required for the PDAC growth promoting effects of the eIF5A factors, indicating a role for SgK269 in the tumourigenesis of PDAC.